Sean Jordan

August 5, 2018

Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis

CONCLUSIONS: Pericytes shield BRAF^(V600E)-PTC cells from targeted therapy via TSP-1 and TGFβ1, suggesting this axis as a new therapeutic target for overcoming resistance to BRAF^(V600E) and TK inhibitors.
Do you like it?0
0 Read more
Prev page
123456789101112131415161718